Sagent announced the launch of Leucovorin Calcium for Injection, a medication consistently appearing on the ASHSP and FDA’s lists of drug shortages.

Leucovorin Calcium, a folic acid derivative, is indicated for rescue after high-dose methotrexate therapy in osteosarcoma; to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists; in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible; and for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.

Leucovorin Calcium for Injection is available in 50mg, 100mg, 200mg, and 35mg single-dose vials that are latex and preservative-free. 

For more information call (866) 625-1618 or visit